Avice­da aims to raise $200M; Ner­viano gets back rights to PARP1 in­hibitor

Plus, news about Maat Phar­ma, Se­cre­tome Ther­a­peu­tics, 35Phar­ma, Medi­gene and Doron Ther­a­peu­tics:

Avice­da Ther­a­peu­tics’ $200M fi­nanc­ing: The Boston-area biotech is look­ing to raise a …

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER